Squarepoint
COGT icon

Squarepoint’s Cogent Biosciences COGT Stock Holding History

Squarepoint’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,500
Closed -$488K – 4697
2024
Q4 		$488K Buy
+62,500
New +$623K ﹤0.01% 3742

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Squarepoint's COGT Position: Q3 2026 in Review

Squarepoint opened a new position in Cogent Biosciences (COGT) in Q3 2026: 12,601 shares worth $403K. The stake represents ﹤0.01% of the portfolio and ranks #3542 among its holdings. This is a return to the name: Squarepoint previously reported a position in COGT as recently as Q1 2026.

Squarepoint first reported a position in COGT in Q3 2018 and has held it in 15 quarters since. The position peaked at $8.71M in Q1 2026. 151 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Squarepoint held 12,601 shares of Cogent Biosciences worth $403K as of Q3 2026.
  • Cogent Biosciences was a new Squarepoint position in Q3 2026.
  • Cogent Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3542 holding.
  • Squarepoint first reported a position in Cogent Biosciences in Q3 2018 and has held it in 15 quarters since.
  • Squarepoint's Cogent Biosciences position peaked at $8.71M in Q1 2026.
  • 151 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.